Antidepressant discontinuation syndrome
- PMID: 28554948
- PMCID: PMC5449237
- DOI: 10.1503/cmaj.160991
Antidepressant discontinuation syndrome
Conflict of interest statement
Competing interests: Verinder Sharma has received grants from Assurex, Genome Canada, Neurocrine Biosciences, Stanley Medical Research Institute and Sunovion Pharmaceuticals. No other competing interests were declared.
References
-
- Diagnostic and statistical manual of mental disorders. 5th ed Arlington (VA): American Psychiatric Association; 2013:712–4.
-
- Fava GA, Gatti A, Belaise C, et al. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom 2015;84:72–81. - PubMed
-
- Berber MJ. FINISH: remembering the discontinuation syndrome. Flu-like symptoms, insomnia, nausea, imbalance, sensory disturbances, and hyperarousal (anxiety/agitation). J Clin Psychiatry 1998;59:255. - PubMed
-
- Warner CH, Bobo W, Warner C, et al. Antidepressant discontinuation syndrome. Am Fam Physician 2006;74:449–56. - PubMed
-
- Ogle NR, Akkerman S. Guidance for the discontinuation or switching of antidepressant therapies in adults. J Pharm Pract 2013;26:389–96. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical